Op Ed: EPA, not just ‘omega-3’, may hold the key to reducing disease risk.
For years, dietary advice for people living with inflammatory bowel disease – conditions like Crohn’s disease and ulcerative colitis – has often included a simple recommendation: take fish oil. The idea is that the omega-3 fatty acids found in fish oil have anti-inflammatory properties, and therefore might help to calm the flares and improve symptoms that are so disruptive to daily life. But, like many things in medicine, the story seems to be a lot more nuanced than we initially thought.
IBD, at its core, represents a misfire of the immune system, where the body mistakenly attacks the gut, leading to chronic inflammation and a host of debilitating symptoms. It is a condition that impacts millions worldwide and can severely reduce quality of life. Current treatments, while improving, aren’t always effective for everyone, and often come with their own set of side effects, leaving many searching for complementary approaches. This is why the potential of nutritional interventions like omega-3 supplementation has always been so appealing.
However, study after study has thrown the benefits of fish oil into question, with many failing to show a clear impact on IBD. This latest research, using a clever technique called ‘Mendelian Randomisation’, offers a fascinating and potentially important explanation for this inconsistency. It doesn’t look at whether taking fish oil in a trial makes a difference, but instead uses people’s genetic variations as a natural experiment to understand the effects of different omega-3s. Essentially, some people are genetically predisposed to have higher levels of specific omega-3 fatty acids in their bodies. Researchers then looked to see if those genetic variations correlated with a lower risk of developing IBD.
What they found wasn’t that ‘omega-3’ as a whole had a protective effect, but something much more specific: higher levels of EPA – one particular type of omega-3 – were linked to a reduced risk of developing IBD in the first place. It appears the benefit isn’t necessarily about boosting all omega-3s, but specifically about elevating EPA. “We’ve been treating ‘omega-3’ as a blanket term for too long, when in reality, its components may have very different effects.”
The study went further, suggesting how EPA might be working. It seems EPA’s benefit isn’t direct, but rather through its interaction with other fatty acids, specifically linoleic acid, and also with how the body processes the amino acid histidine. These interactions influence inflammatory pathways, potentially dampening down the immune response in the gut. They also identified a gene, FADS2, which appears to play a crucial role in all of this, regulating how the body processes omega-3s.
This is important because many over-the-counter fish oil supplements contain a mixture of EPA and DHA – another important omega-3. While DHA is vital for brain health, this research suggests it may not be the key player when it comes to IBD. It raises the question: have we been focusing on the wrong part of the equation?
What does this mean for patients? It’s not a call to immediately stop taking fish oil, but it does suggest that a more targeted approach might be beneficial. Looking for supplements with a higher EPA to DHA ratio, or even focusing on dietary sources rich in EPA, could be a more effective strategy. However, it’s critical to remember that this is still early research, and we need further clinical trials to confirm these findings.
“For too long, we’ve relied on general recommendations instead of really digging into the specifics of how different nutrients actually impact the body.”
Ultimately, this study highlights the importance of precision nutrition and understanding that ‘one size fits all’ rarely applies when it comes to complex conditions like IBD. It’s a reminder that we need to keep questioning our assumptions, even those that seem well-established, and continually refine our understanding of how diet and inflammation interact. This shift towards a more nuanced perspective offers a real opportunity to improve the lives of those living with these challenging conditions.
_This article provides an expert interpretation of published data for educational purposes and should not be considered clinical guidance or a recommendation for patient care._
_Quoted passages represent the interpretive perspective of the editorial author based on the published data and do not constitute the views of any named individual, organisation, or clinical body. They should not be taken as personal medical advice or used to inform treatment decisions._